<?xml version='1.0' encoding='utf-8'?>
<document id="16282832"><sentence text="Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients."><entity charOffset="30-40" id="DDI-PubMed.16282832.s1.e0" text="paroxetine" /><entity charOffset="46-57" id="DDI-PubMed.16282832.s1.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.16282832.s1.e0" e2="DDI-PubMed.16282832.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s1.e0" e2="DDI-PubMed.16282832.s1.e1" /></sentence><sentence text="Augmentation with paroxetine (10-40 mg/d) for antipsychotic treatment may improve the negative symptoms in schizophrenic patients but involves a risk of drug-drug interaction"><entity charOffset="18-28" id="DDI-PubMed.16282832.s2.e0" text="paroxetine" /></sentence><sentence text=" We studied the effects of paroxetine on plasma concentrations of risperidone and 9-hydroxyrisperidone and their clinical symptoms in risperidone-treated patients"><entity charOffset="27-37" id="DDI-PubMed.16282832.s3.e0" text="paroxetine" /><entity charOffset="66-77" id="DDI-PubMed.16282832.s3.e1" text="risperidone" /><entity charOffset="82-102" id="DDI-PubMed.16282832.s3.e2" text="9-hydroxyrisperidone" /><entity charOffset="134-145" id="DDI-PubMed.16282832.s3.e3" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e0" e2="DDI-PubMed.16282832.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e0" e2="DDI-PubMed.16282832.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e0" e2="DDI-PubMed.16282832.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e0" e2="DDI-PubMed.16282832.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e1" e2="DDI-PubMed.16282832.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e1" e2="DDI-PubMed.16282832.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e1" e2="DDI-PubMed.16282832.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e2" e2="DDI-PubMed.16282832.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16282832.s3.e2" e2="DDI-PubMed.16282832.s3.e3" /></sentence><sentence text=" Twelve schizophrenic inpatients with prevailingly negative symptoms receiving risperidone 4 mg/d were, in addition, treated with incremental doses of paroxetine for 12 weeks (10, 20, and 40 mg/d for 4 weeks each)"><entity charOffset="79-90" id="DDI-PubMed.16282832.s4.e0" text="risperidone" /><entity charOffset="151-161" id="DDI-PubMed.16282832.s4.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.16282832.s4.e0" e2="DDI-PubMed.16282832.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s4.e0" e2="DDI-PubMed.16282832.s4.e1" /></sentence><sentence text=" Plasma concentrations of risperidone and 9-hydroxyrisperidone were quantified with liquid chromatography-mass spectrometry mass-mass spectrometry together with clinical assessments before and after each phase of the 3 paroxetine doses"><entity charOffset="26-37" id="DDI-PubMed.16282832.s5.e0" text="risperidone" /><entity charOffset="42-62" id="DDI-PubMed.16282832.s5.e1" text="9-hydroxyrisperidone" /><entity charOffset="219-229" id="DDI-PubMed.16282832.s5.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.16282832.s5.e0" e2="DDI-PubMed.16282832.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s5.e0" e2="DDI-PubMed.16282832.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s5.e0" e2="DDI-PubMed.16282832.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16282832.s5.e1" e2="DDI-PubMed.16282832.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s5.e1" e2="DDI-PubMed.16282832.s5.e2" /></sentence><sentence text=" Risperidone concentrations during coadministration of paroxetine 10, 20, and 40 mg/d were 3"><entity charOffset="1-12" id="DDI-PubMed.16282832.s6.e0" text="Risperidone" /><entity charOffset="55-65" id="DDI-PubMed.16282832.s6.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.16282832.s6.e0" e2="DDI-PubMed.16282832.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s6.e0" e2="DDI-PubMed.16282832.s6.e1" /></sentence><sentence text="8-fold (95% confidence interval, 3" /><sentence text="2-5" /><sentence text="8, P &lt; 0" /><sentence text="01), 7" /><sentence text="1-fold (95% confidence interval, 5" /><sentence text="3-16" /><sentence text="5, P &lt; 0" /><sentence text="01), and 9" /><sentence text="7-fold (95% confidence interval, 7" /><sentence text="8-22" /><sentence text="5, P &lt; 0" /><sentence text="01) higher than that before paroxetine coadministration, respectively"><entity charOffset="28-38" id="DDI-PubMed.16282832.s18.e0" text="paroxetine" /></sentence><sentence text=" Active moiety (risperidone plus 9-hydroxyrisperidone) concentration was not increased during the paroxetine 10 mg/d (1"><entity charOffset="16-27" id="DDI-PubMed.16282832.s19.e0" text="risperidone" /><entity charOffset="33-53" id="DDI-PubMed.16282832.s19.e1" text="9-hydroxyrisperidone" /><entity charOffset="98-108" id="DDI-PubMed.16282832.s19.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.16282832.s19.e0" e2="DDI-PubMed.16282832.s19.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s19.e0" e2="DDI-PubMed.16282832.s19.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s19.e0" e2="DDI-PubMed.16282832.s19.e2" /><pair ddi="false" e1="DDI-PubMed.16282832.s19.e1" e2="DDI-PubMed.16282832.s19.e1" /><pair ddi="false" e1="DDI-PubMed.16282832.s19.e1" e2="DDI-PubMed.16282832.s19.e2" /></sentence><sentence text="3-fold, not significant) or 20 mg/d (1" /><sentence text="6-fold, not significant), but were significantly increased by 1" /><sentence text="8-fold (95% confidence interval, 1" /><sentence text="4-2" /><sentence text="7, P &lt; 0" /><sentence text="05) during the paroxetine 40 mg/d"><entity charOffset="15-25" id="DDI-PubMed.16282832.s25.e0" text="paroxetine" /></sentence><sentence text=" Significant improvement in negative symptoms was observed from 10 to 40 mg/d of paroxetine, whereas scores in extrapyramidal side effects during 20 and 40 mg/d of paroxetine were significantly higher than baseline score"><entity charOffset="81-91" id="DDI-PubMed.16282832.s26.e0" text="paroxetine" /><entity charOffset="164-174" id="DDI-PubMed.16282832.s26.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.16282832.s26.e0" e2="DDI-PubMed.16282832.s26.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s26.e0" e2="DDI-PubMed.16282832.s26.e1" /></sentence><sentence text=" This study indicates that paroxetine increases plasma risperidone concentration and active moiety concentration in a dose-dependent manner"><entity charOffset="27-37" id="DDI-PubMed.16282832.s27.e0" text="paroxetine" /><entity charOffset="55-66" id="DDI-PubMed.16282832.s27.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.16282832.s27.e0" e2="DDI-PubMed.16282832.s27.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s27.e0" e2="DDI-PubMed.16282832.s27.e1" /></sentence><sentence text=" Low-dose coadministration of paroxetine with risperidone may be safe and effective in the treatment of schizophrenic patients with negative symptoms"><entity charOffset="30-40" id="DDI-PubMed.16282832.s28.e0" text="paroxetine" /><entity charOffset="46-57" id="DDI-PubMed.16282832.s28.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.16282832.s28.e0" e2="DDI-PubMed.16282832.s28.e0" /><pair ddi="false" e1="DDI-PubMed.16282832.s28.e0" e2="DDI-PubMed.16282832.s28.e1" /></sentence><sentence text="" /></document>